news

DURECT Announces 1-for-10 Reverse Stock Split

 Nov 28, 2022, 18:46 ET  CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT’s board of directors today determined that the Company will effect a reverse stock split at a …

DURECT Announces 1-for-10 Reverse Stock Split Read More »

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

 Nov 02, 2022, 16:05 ET  –  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET –  AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update. “We are …

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs Read More »

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

 Oct 26, 2022, 08:30 ET  CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022. Wednesday, November 2 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: …

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2 Read More »

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

 Oct 06, 2022, 08:30 ET  AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif., Oct. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced …

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial Read More »

Innocoll and DURECT Announce U.S. launch of POSIMIR®

 Sep 26, 2022, 08:30 ET  POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR ATHLONE, …

Innocoll and DURECT Announce U.S. launch of POSIMIR® Read More »

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

 Sep 06, 2022, 08:00 ET  CUPERTINO, Calif., Sept. 6, 2022 /PRNewswire/ — DURECT Corporation ( Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th annual Global Investment Conference.  Presentation details are as follows: H.C. Wainwright Global Investment Conference Date:            …

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference Read More »

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

 Aug 04, 2022, 16:05 ET  –  Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET –  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif., Aug. 4, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update. “We continue to …

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs Read More »

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

Jul 27, 2022, 16:15 ET CUPERTINO, Calif., July 27, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022. Thursday, August 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 …

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4 Read More »

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

Jul 05, 2022, 08:30 ET CUPERTINO, Calif., July 5, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial …

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer Read More »

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022, 13:53 ET CUPERTINO, Calif., May 18, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of …

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference Read More »

Scroll to Top